Profil
Robert Nowinski is the founder of ContraFect Corp., which was founded in 2008.
He held the title of Chief Executive Officer & Director from 2012 to 2013.
Dr. Nowinski's former jobs include Director at New York Biotechnology Association, Inc., Assistant Professor at the University of Wisconsin, and Associate Professor at Fred Hutchinson Cancer Research Center.
Ehemalige bekannte Positionen von Robert Nowinski
| Unternehmen | Position | Ende |
|---|---|---|
| CONTRAFECT CORPORATION | Vorstandsvorsitzender | 21.11.2013 |
New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an association that promotes the biotechnology industry | Direktor/Vorstandsmitglied | - |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Provides research and testing services | Corporate Officer/Principal | - |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Provides research and testing services | Commercial Services |
New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an association that promotes the biotechnology industry | Commercial Services |
ContraFect Corp.
ContraFect Corp. BiotechnologyHealth Technology Engages in discovery and development of direct lytic agents for life-threatening & drug-resistant infectious diseases | Health Technology |
















